to treat moderately to severely active ulcerative colitis (UC) has an "acceptable" safety profile, new evidence reveals. The updated safety profile of etrasimod, presented at Digestive Disease ...

The US Food and Drug Administration (FDA) has approved etrasimod (Velsipity, Pfizer) for treating moderate to severe active ulcerative colitis (UC) in adults, the company announced on Friday.

Regulators in the US and EU have started a review of Pfizer's S1P receptor modulator etrasimod for people living with moderately-to-severely active ulcerative colitis (UC), with decisions expected ...

Adults with moderately to severely active ulcerative colitis (UC) have a new treatment option with the U.S. Food and Drug Administration’s (FDA) recent approval of the oral medication etrasimod ...

Please provide your email address to receive an email when new articles are posted on . The incidence of adverse events potentially related to serotonin syndrome was low and similar across all ...

On Friday, the FDA approved Pfizer’s etrasimod, branded as Velsipity, for treating adults with the chronic digestive disorder known as ulcerative colitis (UC). The oral, once-daily pill was ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for etrasimod for the treatment of patients with moderately to severely active ulcerative colitis (UC).

There is a simple discount patient access scheme for etrasimod. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

the condition has not responded well enough, or lost response to treatment. Etrasimod is only recommended if the company provides it according to the commercial arrangement. If people with the ...